Nirsevimab effectiveness in MALRTI reduction 0–6 months: beta
Nirsevimab effectiveness in Hospitalizations reduction: beta
Nirsevimab coverage (%): beta PERT
RSV Hospitalization proportion 0–3 months: log-normal
RSV Hospitalization proportion 3–6 months: log-normal
RSV Hospitalization proportion 6–12 months: log-normal
RSV Outpatient proportion 0–3 months: log-normal
RSV Outpatient proportion 3–6 months: log-normal
RSV Outpatient proportion 6–12 months: log-normal
DW moderate: beta
DW severe: beta
Inpatient cost 0–3 months: log-normal BRIGS
Inpatient cost 3–6 months: log-normal BRIGS
Inpatient cost 6–12 months: log-normal BRIGS
Oupatient PC cost: log-normal BRIGS
Outpatient EC cost: log-normal BRIGS
Caregiver wages: log-normal BRIGS
